

Appl. No. 10/091,300
Amdt. dated Jun. 22, 2004
Reply to Office Action dated Dec. 25, 2003

Docket No. 11245/46211

II. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): A method of inhibiting tumor growth comprising administering to a human a therapeutically effective amount of a vascular endothelial growth factor (VEGF) receptor antagonist and a therapeutically effective amount of an epidermal growth factor receptor (EGFR) antagonist, wherein the VEGF receptor antagonist comprises an antibody, or functional equivalent thereof, specific for VEGFR and wherein the EGFR antagonist comprises an antibody, or functional equivalent thereof, specific for EGFR.

Claim 2 (previously presented): The method of claim 1, wherein the tumor overexpresses VEGFR.

Claim 3 (previously presented): The method of claim 1, wherein the tumor is a tumor of the colon.

Claim 4 (previously presented): The method of claim 1, wherein the tumor is a non-small cell lung carcinoma (NSCLC).

Claim 5 (previously presented): The method of claim 1, wherein the VEGF receptor antagonist is administered intravenously.

Claim 6 (withdrawn): The method of claim 1, wherein the VEGF receptor antagonist is administered orally.

Claim 7 (previously presented): The method of claim 1, wherein the VEGF receptor antagonist inhibits binding of VEGFR to its ligand.

Claim 8 (previously presented): The method of claim 1, wherein the VEGF receptor antagonist binds VEGFR.

Appl. No. 10/091,300
Amdt. dated Jun. 22, 2004
Reply to Office Action dated Dec. 25, 2003

Docket No. 11245/46211

Claim 9 (previously presented): The method of claim 1, wherein the VEGF receptor antagonist is an antagonist of *fms*-like tyrosine kinase receptor (flt-1) VEGFR-1.

Claim 10 (withdrawn): The method of claim 1, wherein the VEGF receptor antagonist comprises an antibody, or functional equivalent thereof, specific for VEGFR.

Claim 11 (currently amended): The method of claim 10, wherein the antibody comprises a constant region of a human antibody.

Claim 12 (previously presented): The method of claim 11, wherein the antibody is a chimeric antibody comprising a variable region of a mouse antibody.

Claim 13 (previously presented): The method of claim 11, wherein the antibody is a humanized antibody comprising a variable region having complementarity-determining regions (CDRs) of a mouse antibody and framework regions of a human antibody.

Claim 14 (previously presented): The method of claim 11, wherein the antibody is a human antibody comprising a variable region of a human antibody.

Claim 15 (withdrawn): The method of claim 1, wherein the VEGF receptor antagonist comprises a small molecule specific for VEGFR.

Claim 16 (previously presented): The method of claim 1, wherein the tumor overexpresses EGFR.

Claim 17 (previously presented): The method of claim 1, wherein the EGFR antagonist is administered intravenously.

Claim 18 (withdrawn): The method of claim 1, wherein the EGFR antagonist is administered orally.

Appl. No. 10/091,300
Amtd. dated Jun. 22, 2004
Reply to Office Action dated Dec. 25, 2003

Docket No. 11245/46211

Claim 19 (previously presented): The method of claim 1, wherein the EGFR antagonist inhibits binding of EGFR to its ligand.

Claim 20 (previously presented): The method of claim 1, wherein the EGFR antagonist binds EGFR.

Claim 21 (previously presented): The method of claim 1, wherein the EGFR antagonist inhibits binding of EGFR to ATP.

Claim 22 (withdrawn): The method of claim 1, wherein the EGFR antagonist comprises an antibody, or functional equivalent thereof, specific for EGFR.

Claim 23 (currently amended): The method of claim ~~22~~1, wherein the antibody comprises a constant region of a human antibody.

Claim 24 (previously presented): The method of claim 23, wherein the antibody is a chimeric antibody comprising a variable region of a mouse antibody.

Claim 25 (currently amended): The method of claim ~~22~~23, wherein the antibody is a humanized antibody comprising a variable region having complementarity-determining regions (CDRs) of a mouse antibody and framework regions of a human antibody.

Claim 26 (currently amended): The method of claim ~~22~~23, wherein the antibody is a human antibody comprising a variable region of a human antibody.

Claim 27 (withdrawn): The method of claim 1, wherein the EGFR antagonist comprises a small molecule specific for EGFR.

Claim 28 (previously presented): The method of claim 1, wherein the method further comprises administering a chemotherapeutic agent or radiation.

Appl. No. 10/091,300
Amdt. dated Jun. 22, 2004
Reply to Office Action dated Dec. 25, 2003

Docket No. 11245/46211

Claim 29 (withdrawn): A method of inhibiting tumor growth comprising administering to a human a therapeutically effective amount of a vascular endothelial growth factor (VEGF) receptor antagonist and radiation.

Claim 30 (withdrawn): The method of claim 29, wherein the tumor overexpresses VEGFR.

Claim 31 (withdrawn): The method of claim 29, wherein the tumor is a tumor of the colon.

Claim 32 (withdrawn): The method of claim 29, wherein the tumor is a non-small cell lung carcinoma (NSCLC).

Claim 33 (withdrawn): The method of claim 29, wherein the VEGF receptor antagonist is administered intravenously.

Claim 34 (withdrawn): The method of claim 29, wherein the VEGF receptor antagonist is administered orally.

Claim 35 (withdrawn): The method of claim 29, wherein the VEGF receptor antagonist inhibits binding of VEGFR to its ligand.

Claim 36 (withdrawn): The method of claim 29, wherein the VEGF receptor antagonist binds VEGFR.

Claim 37 (withdrawn): The method of claim 29, wherein the VEGF receptor antagonist is an antagonist of *fms*-like tyrosine kinase receptor (flt-1) VEGFR-1.

Claim 38 (withdrawn): The method of claim 29, wherein the VEGF receptor antagonist comprises an antibody, or functional equivalent thereof, specific for VEGFR.

Appl. No. 10/091,300
Amdt. dated Jun. 22, 2004
Reply to Office Action dated Dec. 25, 2003

Docket No. 11245/46211

Claim 39 (withdrawn): The method of claim 38, wherein the antibody comprises a constant region of a human antibody.

Claim 40 (withdrawn): The method of claim 39, wherein the antibody is a chimeric antibody comprising a variable region of a mouse antibody.

Claim 41 (withdrawn): The method of claim 39, wherein the antibody is a humanized antibody comprising a variable region having complementarity-determining regions (CDRs) of a mouse antibody and framework regions of a human antibody.

Claim 42 (withdrawn): The method of claim 39, wherein the antibody is a human antibody comprising a variable region of a human antibody.

Claim 43 (withdrawn): The method of claim 29, wherein the VEGF receptor antagonist comprises a small molecule specific for VEGFR.

Claim 44 (withdrawn): The method of claim 29, wherein the method further comprises administering radiation.

Claim 45 (withdrawn): A method of inhibiting tumor growth comprising administering to a human a therapeutically effective amount of a vascular endothelial growth factor (VEGF) receptor antagonist and a chemotherapeutic agent.

Claim 46 (withdrawn): The method of claim 45, wherein the tumor overexpresses VEGFR.

Claim 47 (withdrawn): The method of claim 45, wherein the tumor is a tumor of the colon.

Claim 48 (withdrawn): The method of claim 45, wherein the tumor is a non-small cell lung carcinoma (NSCLC).

Appl. No. 10/091,300
Amdt. dated Jun. 22, 2004
Reply to Office Action dated Dec. 25, 2003

Docket No. 11245/46211

Claim 49 (withdrawn): The method of claim 45, wherein the VEGF receptor antagonist is administered intravenously.

Claim 50 (withdrawn): The method of claim 45, wherein the VEGF receptor antagonist is administered orally.

Claim 51 (withdrawn): The method of claim 45, wherein the VEGF receptor antagonist inhibits binding of VEGFR to its ligand.

Claim 52 (withdrawn): The method of claim 45, wherein the VEGF receptor antagonist binds VEGFR.

Claim 53 (withdrawn): The method of claim 45, wherein the VEGF receptor antagonist is an antagonist of *fms*-like tyrosine kinase receptor (flt-1) VEGFR-1.

Claim 54 (withdrawn): The method of claim 45, wherein the VEGF receptor antagonist comprises an antibody, or functional equivalent thereof, specific for VEGFR.

Claim 55 (withdrawn): The method of claim 45, wherein the antibody comprises a constant region of a human antibody.

Claim 56 (withdrawn): The method of claim 55, wherein the antibody is a chimeric antibody comprising a variable region of a mouse antibody.

Claim 57 (withdrawn): The method of claim 55, wherein the antibody is a humanized antibody comprising a variable region having complementarity-determining regions (CDRs) of a mouse antibody and framework regions of a human antibody.

Claim 58 (withdrawn): The method of claim 55, wherein the antibody is a human antibody comprising a variable region of a human antibody.

Appl. No. 10/091,300
Amdt. dated Jun. 22, 2004
Reply to Office Action dated Dec. 25, 2003

Docket No. 11245/46211

Claim 59 (withdrawn): The method of claim 45, wherein the VEGF receptor antagonist comprises a small molecule specific for VEGFR.

Claim 60 (withdrawn): The method of claim 45, wherein the chemotherapeutic agent is not conjugated to the VEGF receptor antagonist.

Claim 61 (withdrawn): The method of claim 45, wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, doxorubicin, taxol and combinations thereof.

Claim 62 (currently amended): A kit for inhibiting tumor growth comprising a therapeutically effective amount of an epidermal growth factor receptor (EGFR) antagonist and a therapeutically effective amount of a vascular endothelial growth factor (VEGF) receptor antagonist, wherein the VEGF receptor antagonist comprises an antibody, or functional equivalent thereof, specific for VEGFR and wherein the EGFR antagonist comprises an antibody, or functional equivalent thereof, specific for EGFR.

Claim 63 (withdrawn): The kit of claim 62, wherein the EGFR antagonist comprises an antibody, or functional equivalent thereof, specific for EGFR.

Claim 64 (withdrawn): The kit of claim 62, wherein the EGFR antagonist comprises a small molecule specific for EGFR.

Claim 65 (withdrawn): The kit of claim 62, wherein the VEGFR antagonist comprises an antibody, or functional equivalent thereof, specific for VEGFR.

Claim 66 (withdrawn): The kit of claim 62, wherein the VEGFR antagonist comprises a small molecule specific for VEGFR.

Claim 67 (previously presented): The kit of claim 62, wherein the kit further comprises a chemotherapeutic agent or radiation.